Esperion Therapeutics (ESPR) Short Interest Ratio & Short Volume $0.96 +0.05 (+5.80%) Closing price 04/29/2025 04:00 PM EasternExtended Trading$0.95 -0.01 (-0.72%) As of 04/29/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Esperion Therapeutics Short Interest DataEsperion Therapeutics (ESPR) has a short interest of 30.03 million shares, representing 15.43% of the float (the number of shares available for trading by the public). This marks a 7.17% increase in short interest from the previous month. The short interest ratio (days to cover) is 6.6, indicating that it would take 6.6 days of the average trading volume of 5.65 million shares to cover all short positions.Current Short Interest30,030,000 sharesPrevious Short Interest28,020,000 sharesChange Vs. Previous Month+7.17%Dollar Volume Sold Short$29.90 millionShort Interest Ratio6.6 Days to CoverLast Record DateApril 15, 2025Outstanding Shares198,149,000 sharesFloat Size194,670,000 sharesShort Percent of Float15.43%Today's Trading Volume3,880,749 sharesAverage Trading Volume5,653,183 sharesToday's Volume Vs. Average69% Short Selling Esperion Therapeutics? Sign up to receive the latest short interest report for Esperion Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartESPR Short Interest Over TimeESPR Days to Cover Over TimeESPR Percentage of Float Shorted Over Time Esperion Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/202530,030,000 shares $29.90 million +7.2%15.4%6.6 $1.00 3/31/202528,020,000 shares $40.35 million -3.0%14.4%6.4 $1.44 3/15/202528,900,000 shares $43.35 million -0.8%14.9%6.8 $1.50 2/28/202529,140,000 shares $49.54 million +3.7%14.9%5.4 $1.70 2/15/202528,100,000 shares $52.27 million -10.1%14.4%5.1 $1.86 1/31/202531,240,000 shares $55.92 million -8.1%16.0%5 $1.79 1/15/202533,980,000 shares $75.10 million +5.0%17.4%5.6 $2.21 12/31/202432,350,000 shares $71.17 million +27.0%16.6%5.7 $2.20 12/15/202425,470,000 shares $57.31 million -16.5%13.1%4.6 $2.25 11/30/202430,490,000 shares $85.37 million -2.4%15.6%6.7 $2.80 Get the Latest News and Ratings for ESPR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/15/202431,250,000 shares $66.25 million -6.6%16.0%8.2 $2.12 10/31/202433,460,000 shares $68.26 million -5.5%17.2%8.8 $2.04 10/15/202435,390,000 shares $75.38 million -5.6%18.2%9.7 $2.13 9/30/202437,470,000 shares $61.83 million -1.6%19.3%9.3 $1.65 9/15/202438,090,000 shares $72.75 million -5.8%19.6%6.9 $1.91 8/31/202440,440,000 shares $74.01 million -3.1%20.8%6.4 $1.83 8/15/202441,730,000 shares $82.21 million +9.4%21.5%6 $1.97 7/31/202438,140,000 shares $88.10 million -3.3%22.2%5.1 $2.31 7/15/202439,420,000 shares $98.55 million +67.4%25.5%4.8 $2.50 6/30/202423,550,000 shares $52.28 million -5.4%15.2%2.8 $2.22 6/15/202424,890,000 shares $74.42 million +13.7%16.1%3 $2.99 5/31/202421,890,000 shares $47.28 million -12.1%14.2%2.8 $2.16 5/15/202424,910,000 shares $57.29 million +25.4%16.1%3.4 $2.30 4/30/202419,870,000 shares $39.14 million +6.8%11.8%2.9 $1.97 4/15/202418,600,000 shares $35.99 million -6.6%11.0%3 $1.94 3/31/202419,920,000 shares $53.39 million +12.7%11.8%3 $2.68 3/15/202417,670,000 shares $36.58 million +4.3%10.5%2.8 $2.07 2/29/202416,950,000 shares $42.54 million -8.7%10.0%2.8 $2.51 2/15/202418,570,000 shares $49.40 million -7.5%11.0%3 $2.66 1/31/202420,070,000 shares $42.95 million -0.6%11.9%3.3 $2.14 1/15/202420,200,000 shares $61.00 million +1.4%17.9%3.7 $3.02 12/31/202319,920,000 shares $59.56 million +9.2%17.7%4.3 $2.99 12/15/202318,240,000 shares $33.20 million +2.8%16.2%4.3 $1.82 11/30/202317,740,000 shares $23.59 million -3.1%15.7%4.6 $1.33 11/15/202318,310,000 shares $21.06 million +0.5%16.2%4.7 $1.15 10/31/202318,220,000 shares $15.10 million -5.2%17.2%4.8 $0.83 10/15/202319,220,000 shares $15.95 million -3.0%18.1%5 $0.83 9/30/202319,810,000 shares $19.41 million +20.4%18.7%5.5 $0.98 9/15/202316,460,000 shares $23.37 million +8.4%15.5%4.7 $1.42 8/31/202315,180,000 shares $24.29 million +8.5%14.3%4.8 $1.60What if America bought gold like it used to? (Ad)History Says Gold Wins When This Signal Flashes — and It’s Flashing Now Every time the Buffett Indicator has hit extreme levels, stocks have crashed — and gold has dominated the decade that followed. Today, the Buffett Indicator is at its highest reading in history… and Buffett himself is sitting on an unprecedented $325 billion cash pile. Sources say he’s preparing to deploy it — not into stocks, but into gold. Garrett Goggin has uncovered which gold company could be his next big move.Find out which gold company Buffett is likely to back — and how to get ahead of the coming gold deca 8/15/202313,990,000 shares $22.94 million +4.3%13.2%5 $1.64 7/31/202313,410,000 shares $21.05 million +2.9%12.7%4.9 $1.57 7/15/202313,030,000 shares $18.76 million +4.2%13.9%5.4 $1.44 6/30/202312,510,000 shares $17.39 million -9.9%13.3%5.1 $1.39 6/15/202313,880,000 shares $19.02 million +3.8%14.8%5 $1.37 5/31/202313,370,000 shares $18.18 million -8.4%14.3%3.6 $1.36 5/15/202314,600,000 shares $24.82 million No Change15.6%3.5 $1.70 10/31/202214,030,000 shares $114.06 million +5.3%N/A11.6 $8.13 10/15/202213,330,000 shares $101.31 million +6.6%N/A11.5 $7.60 9/30/202212,500,000 shares $83.75 million -0.9%N/A12.1 $6.70 9/15/202212,610,000 shares $94.83 million -5.5%N/A12.6 $7.52 8/31/202213,350,000 shares $99.59 million +8.6%N/A13.9 $7.46 8/15/202212,290,000 shares $81.97 million -1.8%N/A13.7 $6.67 7/31/202212,520,000 shares $72.24 million +3.2%N/A12.9 $5.77 7/15/202212,130,000 shares $81.39 million +2.6%N/A11.8 $6.71 6/30/202211,820,000 shares $75.18 million +6.8%N/A10.2 $6.36 6/15/202211,070,000 shares $59.00 million -4.2%N/A9.1 $5.33 5/31/202211,560,000 shares $65.89 million +13.7%N/A8.7 $5.70 5/15/202210,170,000 shares $58.78 million +15.8%N/A7.3 $5.78 4/30/20228,780,000 shares $49.87 million +10.0%N/A6.4 $5.68 4/15/20227,980,000 shares $47.00 million +8.7%N/A6.3 $5.89 3/31/20227,340,000 shares $34.06 million +36.7%N/A0 $4.64 3/15/20225,370,000 shares $24.70 million +29.7%N/A4 $4.60 2/28/20224,140,000 shares $16.93 million +18.0%N/A2.7 $4.09 2/15/20223,510,000 shares $14.00 million +11.4%N/A1.6 $3.99 1/31/20223,150,000 shares $13.51 million -3.7%N/A1.4 $4.29 1/15/20223,270,000 shares $12.85 million -62.2%N/A1.5 $3.93 12/31/20218,650,000 shares $43.25 million +10.6%N/A3.9 $5.00 12/15/20217,820,000 shares $41.84 million -20.9%N/A3.8 $5.35 11/30/20219,880,000 shares $86.25 million +11.5%N/A5.2 $8.73 11/15/20218,860,000 shares $77.26 million -3.5%N/A8.1 $8.72 10/29/20219,180,000 shares $82.07 million +15.2%N/A9.5 $8.94 10/15/20217,970,000 shares $72.85 million +8.7%28.7%9.3 $9.14 9/30/20217,330,000 shares $88.33 million -10.0%26.4%9.7 $12.05 9/15/20218,140,000 shares $92.31 million +0.5%29.3%11.4 $11.34 8/31/20218,100,000 shares $105.46 million -7.1%29.2%14.1 $13.02 8/13/20218,720,000 shares $121.30 million -3.3%31.4%15.4 $13.91 7/30/20219,020,000 shares $138.82 million -5.1%32.5%14.5 $15.39 7/15/20219,500,000 shares $167.96 million +5.2%34.3%14.1 $17.68 6/30/20219,030,000 shares $190.98 million +0.9%32.6%13.7 $21.15 6/15/20218,950,000 shares $221.96 million -0.4%32.3%14.2 $24.80 5/28/20218,990,000 shares $178.99 million -1.5%32.4%13.8 $19.91 5/14/20219,130,000 shares $204.51 million -5.8%N/A13.4 $22.40 4/30/20219,690,000 shares $264.63 million -0.8%40.8%14.1 $27.31 4/15/20219,770,000 shares $265.26 million +3.3%N/A14 $27.15 3/31/20219,460,000 shares $259.58 million -3.1%N/A12.1 $27.44 3/15/20219,760,000 shares $296.12 million -3.5%N/A11.7 $30.34 2/26/202110,110,000 shares $279.84 million +5.9%N/A12.2 $27.68 2/12/20219,550,000 shares $293.57 million -5.8%35.5%11.7 $30.74 1/29/202110,140,000 shares $325.70 million -8.5%37.7%12.3 $32.12What if America bought gold like it used to? (Ad)History Says Gold Wins When This Signal Flashes — and It’s Flashing Now Every time the Buffett Indicator has hit extreme levels, stocks have crashed — and gold has dominated the decade that followed. Today, the Buffett Indicator is at its highest reading in history… and Buffett himself is sitting on an unprecedented $325 billion cash pile. Sources say he’s preparing to deploy it — not into stocks, but into gold. Garrett Goggin has uncovered which gold company could be his next big move.Find out which gold company Buffett is likely to back — and how to get ahead of the coming gold deca 1/15/202111,080,000 shares $296.39 million +2.8%N/A12.9 $26.75 12/31/202010,780,000 shares $303.46 million +6.5%N/A15.7 $28.15 12/15/202010,120,000 shares $299.35 million +3.5%44.0%15.5 $29.58 11/30/20209,780,000 shares $264.26 million +0.9%42.5%16 $27.02 11/15/20209,690,000 shares $278.01 million -3.7%42.1%15.2 $28.69 10/30/202010,060,000 shares $315.48 million -0.7%43.7%16.3 $31.36 10/15/202010,130,000 shares $342.19 million -9.1%N/A17.5 $33.78 9/30/202011,140,000 shares $414.07 million -0.3%N/A18.6 $37.17 9/15/202011,170,000 shares $414.74 million -3.5%N/A18 $37.13 8/31/202011,570,000 shares $417.68 million +5.1%N/A17.6 $36.10 8/14/202011,010,000 shares $361.24 million +1.2%40.9%16.2 $32.81 7/31/202010,880,000 shares $409.41 million +3.8%40.7%15.8 $37.63 7/15/202010,480,000 shares $496.96 million +3.5%39.2%16.3 $47.42 6/30/202010,130,000 shares $482.59 million +8.1%37.9%15.4 $47.64 6/15/20209,370,000 shares $411.81 million +15.4%35.1%13.6 $43.95 5/29/20208,120,000 shares $332.43 million -2.8%30.4%10.4 $40.94 5/15/20208,350,000 shares $372.58 million +7.6%31.2%9.9 $44.62 4/30/20207,760,000 shares $307.30 million +2.0%29.0%8.2 $39.60 ESPR Short Interest - Frequently Asked Questions What is Esperion Therapeutics' current short interest? Short interest is the volume of Esperion Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 15th, investors have sold 30,030,000 shares of ESPR short. 15.43% of Esperion Therapeutics' shares are currently sold short. Learn More on Esperion Therapeutics' current short interest. What is a good short interest ratio for Esperion Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ESPR shares currently have a short interest ratio of 7.0. Learn More on Esperion Therapeutics's short interest ratio. Which institutional investors are shorting Esperion Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Esperion Therapeutics: GTS Securities LLC, Wolverine Trading LLC, Squarepoint Ops LLC, Group One Trading LLC, Citadel Advisors LLC, Jane Street Group LLC, Concourse Financial Group Securities Inc., Walleye Trading LLC, Walleye Capital LLC, and Bank of Montreal Can. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Esperion Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 15.43% of Esperion Therapeutics' floating shares are currently sold short. Is Esperion Therapeutics' short interest increasing or decreasing? Esperion Therapeutics saw a increase in short interest in April. As of April 15th, there was short interest totaling 30,030,000 shares, an increase of 7.2% from the previous total of 28,020,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Esperion Therapeutics' float size? Esperion Therapeutics currently has issued a total of 198,149,000 shares. Some of Esperion Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Esperion Therapeutics currently has a public float of 194,670,000 shares. How does Esperion Therapeutics' short interest compare to its competitors? 15.43% of Esperion Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Esperion Therapeutics: Nuvation Bio Inc. (13.58%), Cronos Group Inc. (2.04%), LENZ Therapeutics, Inc. (12.78%), Phibro Animal Health Co. (4.32%), ArriVent BioPharma, Inc. (27.59%), Evolus, Inc. (12.90%), Dianthus Therapeutics, Inc. (26.50%), AnaptysBio, Inc. (53.39%), Xeris Biopharma Holdings, Inc. (13.39%), Arbutus Biopharma Co. (6.07%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Incorporated ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management, Inc. ($3.86 billion), Capital One Financial Co. ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Co. ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks. What does it mean to sell short Esperion Therapeutics stock? Short selling ESPR is an investing strategy that aims to generate trading profit from Esperion Therapeutics as its price is falling. ESPR shares are trading up $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Esperion Therapeutics? A short squeeze for Esperion Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ESPR, which in turn drives the price of the stock up even further. How often is Esperion Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ESPR, twice per month. The most recent reporting period available is April, 15 2025. More Short Interest Resources from MarketBeat Related Companies Nuvation Bio Short Squeeze Cronos Group Short Squeeze LENZ Therapeutics Short Squeeze Phibro Animal Health Short Squeeze ArriVent BioPharma Short Squeeze Evolus Short Squeeze Dianthus Therapeutics Short Squeeze AnaptysBio Short Squeeze Xeris Biopharma Short Squeeze Arbutus Biopharma Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ESPR) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored#1 AI play of the decade…? (The answer will shock you)Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ESPR Stock Free ESPR Stock Alerts